Clinical trial
Safety Assessment of a Multipeptide-gene Vaccine in CML
NCT00455221 · Tehran University of Medical Sciences, Other · Completed
Key facts
| NCT number | NCT00455221 |
|---|---|
| Title | Safety Assessment of a Multipeptide-gene Vaccine in CML |
| Official title | Safety Assessment of a Peptide Vaccine Derived From Bcr-abl Along With Cytokine Genes in CML Patients Undergoing Imatinib Treatment |
| Lead sponsor | Tehran University of Medical Sciences, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Chronic |
| Intervention type | Biological, Genetic |
| Interventions | Bcr-abl multipeptide vaccine, Cytokine gene adjuvant |
| Enrollment | 12 |
| Start date | Feb 1, 2008 |
| Primary completion | Dec 1, 2010 |
| Completion | Nov 1, 2011 |
| First posted | Apr 3, 2007 |
| Last update posted | Jun 4, 2012 |
| Countries | Iran |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: